Maxim Thinks ACHV Stock Can Double

2 small-cap stocks in focus this morning are ACHV and HEB

Jun 14, 2019 at 10:19 AM
facebook twitter linkedin

Achieve Life Sciences Inc (NASDAQ:ACHV) has had a volatile year on the charts, making several sharp moves in both directions in 2019. Today, the shares are slightly lower, trading at $2.64, despite brokerage firm Maxim beginning coverage with a "buy" rating and $6 price target.

Before today, Ladenburg Thalmann was the only firm covering ACHV shares, just raising its price target earlier this week to $20 from $12. At current levels, the shares are testing their 200-day moving average, after coming into 2019 at $1.21.

Another name on Maxim's radar is Hemispherx Biopharma Inc (NYSEAMERICAN:HEB). The analysts set a $8 price target and a "buy" rating on the security, which was last seen trading at $5.14, down 4% this morning. The only other analyst in coverage has a "buy" rating, as well, and a price target of $26.40.

Longer term, the shares have struggled, down almost 60% in the past year. Given this weakness, it's somewhat surprising that short interest accounts for less than 4% of the security's total float.



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners